Research programme: cancer and viral infection therapeutics - AustinPx
Alternative Names: K 002; K 003Latest Information Update: 26 Sep 2023
At a glance
- Originator DisperSol Technologies
- Developer AustinPx
- Class Antineoplastics; Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Viral infections
Most Recent Events
- 26 Sep 2023 Discontinued - Preclinical for Cancer in USA (PO)
- 26 Sep 2023 Discontinued - Preclinical for Viral infections in USA (PO)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Cancer in USA (PO)